Key Highlights

  • Alector licensed its AL050 program to Genentech for $100 million upfront plus up to $1.17 billion in milestones.
  • AL050 is a preclinical program targeting GCase, an enzyme linked to Parkinson's and other neurodegenerative conditions.
  • Milestone payments are contingent on development, regulatory or sales goals and are not guaranteed.
  • The deal gives Genentech global rights to lead development of the program going forward.

Alector shares surged on Monday, Oct. 5, after the biotech licensed its early-stage Parkinson's and neurodegeneration program to Roche's Genentech for $100 million upfront and up to $1.17 billion in milestones.

The Deal

Alector (NASDAQ:ALEC) surged on Monday, Oct. 5, after announcing a global license of its AL050 program to Genentech, a member of the Roche Group. The stock leapt in premarket trading and was still sharply higher in early trading, though reports differed widely on the size of the move. It was among the standout gainers on the Russell 2000.

Under the deal, Alector receives $100 million upfront. It is also eligible for up to $1.17 billion in milestone payments, plus tiered royalties on future sales.

What AL050 Is

AL050 is a preclinical program targeting GCase, an enzyme linked to Parkinson's disease and other neurodegenerative conditions. Preclinical means it has not yet been tested in human trials.

Variations in the gene that makes GCase are among the most common known genetic risk factors for Parkinson's, which is why the enzyme has drawn interest from drug developers. By licensing the program to Genentech, Alector hands development to a much larger partner with deep resources.

For a smaller biotech, a deal like this does two things. The upfront payment brings in cash immediately, which can fund other work without selling new shares. And the backing of a major drugmaker can be seen by investors as a vote of confidence in the program.

Milestone payments are contingent. They are paid only if the program hits specific development, regulatory or sales goals, so the headline figure of up to $1.17 billion is not guaranteed. Royalties depend on any eventual product reaching the market, which for a preclinical program remains a distant and uncertain prospect.

Still, the structure gives Alector exposure to the upside if Genentech succeeds, while shifting much of the cost of development onto its partner. Genentech gains global rights to the program, which means it will lead work on AL050 from here.

A Mixed Day for Health Care

Alector's jump came on a tough day for large parts of health care, which was the weakest sector at midday. Merck (NYSE:MRK) was the worst stock in the Dow, and Bristol-Myers Squibb (NYSE:BMY) fell after Leerink Partners downgraded it, citing pipeline risks.

Smaller biotechs with specific news did better. Vaxcyte (NASDAQ:PCVX) soared on positive Vaccine data, Genmab (NASDAQ:GMAB) jumped on lymphoma results with AbbVie (NYSE:ABBV), and Alvotech (NASDAQ:ALVO) rose after an FDA approval that doubles the drug-substance Manufacturing capacity available for the US market for its Humira biosimilar.

The Market Backdrop

Small caps rose. The Russell 2000 gained 14.24 points to 2,847.14. The Nasdaq Composite climbed 286.45 points to a record 27,477.31, the S&P 500 rose 51.23 points to 7,773.95, just shy of its summer record, and the Dow added 90.94 points to 51,267.90.

Friday's weak September jobs report, with payrolls up just 29,000, cut bets on another Fed hike in October. Still, the 10-year Treasury Yield climbed to its highest level since 2002. Rate expectations matter for biotechs, which often depend on outside funding to advance their programs.

What to Watch Next

For Alector, the next steps depend on Genentech's development plans for AL050, along with updates on the company's remaining pipeline. Its next Quarterly Report should show how the upfront payment changes its cash position.

On the macro side, the Fed releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. For Alector, Genentech's development plans for AL050 will likely carry more weight than anything on the Fed's calendar.